persist
rubella
viru
rv
infect
associ
variou
patholog
congenit
rubella
syndrom
fuch
uveiti
cutan
granuloma
patient
primari
immun
defici
pid
current
drug
treat
rv
infect
nitazoxanid
ntz
fdaapprov
drug
parasit
infect
recent
shown
broadspectrum
antivir
activ
found
empir
therapi
oral
ntz
associ
declineelimin
rv
antigen
lesion
pid
patient
rv
posit
granuloma
peginterferon
treatment
effect
addit
character
effect
ntz
cell
cultur
model
persist
rv
infect
ntz
significantli
inhibit
rv
replic
primari
cultur
human
umbil
vein
endotheli
cell
huvec
vero
epitheli
cell
line
dose
depend
manner
averag
inhibitori
concentr
rv
strain
repres
current
circul
genotyp
inhibit
similar
extent
ntz
affect
earli
late
stage
infect
inhibit
synthesi
cellular
rv
rna
interf
intracellular
traffick
rv
surfac
glycoprotein
result
suggest
potenti
applic
ntz
treatment
persist
rubella
infect
studi
requir
rubella
viru
rv
small
envelop
viru
posit
singlestrand
rna
genom
famili
togavirida
genu
rubiviru
rv
import
human
pathogen
abil
caus
multipl
patholog
establish
persist
infect
immun
privileg
bodi
site
fetus
first
trimest
pregnanc
persist
infect
fetu
immatur
immun
system
result
multipl
birth
defect
call
congenit
rubella
syndrom
cr
driscol
plotkin
et
al
tonduri
smith
postrubella
enceph
often
fatal
document
follow
persist
infect
brain
wild
type
vaccin
virus
chaari
et
al
guler
et
al
wolinski
et
al
chronic
recurr
rubellaassoci
arthriti
develop
immun
adult
fraser
et
al
tingl
et
al
granuloma
person
primari
immun
defici
pid
fuch
uveiti
newli
suggest
diseas
associ
decadeslong
persist
rv
infect
abernathi
et
al
bodem
et
al
doan
et
al
perelygina
et
al
current
antivir
drug
treat
rubella
infect
identif
treatment
chronic
rubella
diseas
benefici
nitazoxanid
ntz
fdaapprov
drug
licens
us
alinia
treatment
enteritid
due
parasit
protozoa
anaerob
bacteria
cohen
fox
saravolatz
ntz
also
shown
broadspectrum
antivir
activ
current
phase
iiiii
clinic
trial
hepat
c
influenza
virus
rotaviru
noroviru
korba
et
al
rossignol
rossignol
et
al
signific
drugrel
health
issu
report
drug
safe
approv
pediatr
use
cohen
fox
saravolatz
ntz
target
host
function
essenti
viral
replic
pathogenspecif
sever
antivir
mechan
propos
induct
innat
immun
downregul
viral
receptor
interfer
matur
viral
structur
protein
posttransl
stage
probabl
due
deplet
induc
chronic
subleth
stress
endoplasm
reticulum
er
ashiru
et
al
elazar
et
al
gekong
et
al
korba
et
al
la
frazia
et
al
rossignol
et
al
trabattoni
et
al
studi
investig
abil
ntz
control
rv
replic
cell
cultur
explor
mechan
antirv
activ
ntz
system
vitro
studi
confirm
ntz
inhibit
rv
replic
ntz
treatment
pid
patient
show
therapeut
efficaci
human
umbil
vein
endotheli
cell
huvec
lonza
cultur
endotheli
growth
medium
lonza
atcc
vero
cell
atcc
ccl
maintain
dulbecco
modifi
eagl
medium
invitrogen
contain
fb
atlanta
biolog
supplement
gentamicin
invitrogen
vaccin
strain
clinic
isol
rvi
dezhou
rvdz
rviseattl
rvi
burlington
rviyavapai
rvi
redmond
propag
vero
cell
nitazoxanid
sigmaaldrich
dissolv
dimethyl
sulfoxid
dmso
concentr
mgml
medium
contain
dmso
use
vehicl
control
experi
femal
patient
born
receiv
immun
measl
rubella
age
year
later
diagnos
combin
immunodefici
involv
defect
band
tcell
matur
receiv
immunoglobulin
replac
treatment
sinc
patient
suffer
chronic
skin
lesion
right
hand
arm
bone
skin
biopsi
show
granulomat
histolog
caus
infecti
agent
identifi
fig
frequent
empir
treatment
bacteria
mycobacteria
fungi
given
without
signific
benefit
one
individu
patient
pid
whose
cutan
granuloma
discov
posit
vaccin
rv
strain
ra
perelygina
et
al
patient
develop
progress
multifoc
leukoencephalopathi
pml
associ
polyomaviru
jc
jcv
effect
peginterferon
ntz
treatment
control
jcv
modifi
pml
cours
describ
separ
public
also
includ
detail
timelin
treatment
descript
patient
immun
statu
hautala
et
al
februari
patient
develop
septic
aspir
pneumonia
result
death
inform
consent
obtain
patient
caregiv
attend
physician
accordingli
standard
practic
finland
project
determin
cdc
nonhuman
research
cdc
restrict
access
person
identifi
inform
cell
seed
plate
densiti
cell
per
well
treat
serial
dilut
ntz
h
quadrupl
ntz
cytotox
growth
inhibit
assess
ldhbase
cytotox
detect
kit
roch
use
modifi
protocol
smith
et
al
confluent
cell
monolay
plate
infect
rv
moi
pfuml
unless
differ
specifi
viru
adsorpt
monolay
wash
three
time
pb
treat
ntz
dmso
supernat
collect
h
postinfect
hpi
titer
vero
cell
immunocolorimetr
histolog
immunofluoresc
stain
show
distribut
rv
capsid
protein
red
granuloma
epidermi
skin
lesion
treatment
interferon
oral
ntz
space
one
month
apart
nuclei
stain
dapi
multipl
cluster
rvposit
cell
easili
detect
prior
ntz
treatment
note
lack
rv
stain
epidermi
singl
weakli
posit
cell
white
arrow
granuloma
ntz
treatment
interpret
refer
colour
figur
legend
reader
refer
web
version
articl
plaqu
assay
chen
et
al
ntz
concentr
produc
reduct
viru
yield
ic
ic
determin
interpol
doserespons
curv
use
prism
softwar
graphpad
softwar
inc
timeofaddit
experi
huvec
monolay
treat
ntz
h
infect
viru
adsorpt
period
hpi
rv
moi
viru
yield
determin
either
dpi
pretreat
cultur
day
posttreat
rna
fluoresc
situ
hybrid
rnafish
cell
grown
polylysin
coat
chamber
slide
bd
bioscienc
infect
rv
moi
treat
ntz
day
rv
rnafish
use
quantigen
viewrna
assay
kit
affymetrix
describ
perelygina
et
al
mixtur
probe
set
either
neg
positivestrand
rv
genom
rna
influenza
neg
strand
neg
control
fitclabel
probe
set
peptidylpropyl
isomeras
b
ppib
gene
use
imag
taken
use
axioimag
system
axiovis
softwar
zeiss
germani
fluoresc
intens
six
microscop
field
cell
per
field
measur
use
imagej
schindelin
et
al
newli
synthes
rna
detect
use
clickit
rna
imag
kit
invitrogen
accord
manufactur
instruct
briefli
cell
treat
either
ntz
dmso
h
ml
actinomycin
h
follow
incub
mm
uridin
cell
fix
paraformaldehyd
permeabil
triton
incub
clickit
reaction
cocktail
contain
alexa
fluor
fluoresc
intens
nuclei
n
condit
microscop
imag
quantit
use
imagej
ifa
wb
analys
viral
antigen
perform
describ
perelygina
et
al
use
mous
monoclon
antibodi
specif
rubella
capsid
protein
abcam
glycoprotein
meridian
life
scienc
glycoprotein
cdc
core
facil
percentag
rv
infect
cell
quantifi
count
cell
random
microscop
field
immunofluoresc
stain
formalin
fix
paraffinembed
tissu
section
perform
describ
earlier
perelygina
et
al
statist
analys
perform
graphpad
prizm
softwar
graphpad
softwar
inc
use
student
ttest
unpair
data
p
valu
consid
signific
immunofluoresc
stain
skin
biopsi
obtain
lesion
patient
arm
reveal
presenc
rv
antigen
epidermi
cutan
granuloma
fig
granuloma
progress
convent
therapi
ineffect
empir
antivir
treatment
peginterferon
given
accord
hepat
c
regimen
hoofnagl
seeff
patient
tire
dizzi
lost
appetit
high
dose
drug
given
also
develop
thrombocytopenia
treatment
discontinu
due
advers
reaction
drug
one
month
later
patient
given
mg
oral
ntz
twice
daili
two
month
well
toler
obviou
neg
sideeffect
note
effect
treatment
evalu
immunostain
skin
biopsi
taken
lesion
rv
peginterferon
treatment
effect
amount
distribut
rv
antigen
ntz
treatment
result
almost
complet
elimin
rv
antigen
lesion
antigen
detect
epidermi
sporad
weakli
stain
macrophag
observ
sequenti
section
biopsi
fig
treatment
provid
notic
clinic
improv
remain
five
month
life
skin
secondari
bacteri
infect
follow
ntz
treatment
patient
treat
antibiot
effect
ntz
treatment
rv
replic
investig
use
previous
describ
vitro
model
rv
persist
huvec
primari
cultur
huvec
monolay
infect
rvdz
moi
treat
differ
concentr
ntz
dmso
h
viru
titer
medium
determin
plaqu
assay
percentag
infect
cell
estim
count
cell
follow
ifa
observ
dosedepend
inhibit
rv
product
concurr
reduct
number
rvposit
cell
ntztreat
cultur
fig
posit
cell
well
treat
ntz
almost
cell
posit
control
well
posit
cell
observ
treatment
ntz
effect
ntz
treatment
cell
viabil
prolifer
determin
ldh
assay
uninfect
huvec
ntz
cytotox
less
cell
treat
less
ntz
howev
concord
publish
result
ashiru
et
al
ntz
cytostat
concentr
higher
fig
therefor
use
ntz
subsequ
experi
due
low
cytotox
minim
effect
cell
prolifer
inhibit
rv
infect
next
compar
ntz
effect
differ
cell
type
huvec
vero
cell
monolay
treat
serial
dilut
ntz
follow
rvdz
infect
moi
viral
yield
determin
hpi
determin
whether
ntz
inhibit
infect
differ
rv
strain
infect
huvec
monolay
either
vaccin
strain
five
wild
type
rv
repres
current
circul
genotyp
infect
cultur
treat
ntz
h
viru
titer
media
determin
plaqu
assay
tabl
data
indic
replic
differ
rv
strain
inhibit
similar
extent
huvec
infect
rvdz
moi
moi
cell
becam
infect
initi
viru
adsorpt
monolay
treat
ntz
day
viru
titer
medium
determin
plaqu
assay
percentag
infect
cell
estim
ifa
infect
cell
detect
ntztreat
well
rv
yield
substanti
inhibit
tabl
thu
ntz
prevent
rv
replic
spread
low
multipl
infect
identifi
stage
rv
replic
cycl
affect
ntz
timeofaddit
experi
perform
use
rv
infect
moi
huvec
monolay
treat
ntz
prior
rvdz
adsorpt
adsorpt
postadsorpt
ntz
treatment
prior
adsorpt
effect
rv
replic
fig
minim
nonsignific
reduct
rv
yield
observ
drug
present
adsorpt
step
suggest
ntz
interfer
viru
infect
cell
entri
effect
inhibit
rv
replic
observ
treatment
initi
earli
stage
replic
cycl
hpi
although
less
effect
treatment
initi
later
stage
hpi
still
abl
significantli
block
viru
product
data
suggest
ntz
inhibit
rv
replic
one
stage
replic
cycl
albeit
differ
effici
howev
dosedepend
effect
ntz
differ
cell
cultur
vero
huvec
monolay
infect
rvdz
moi
treat
differ
concentr
ntz
immedi
viru
adsorpt
viru
titer
medium
determin
hpi
plaqu
assay
rvdz
titer
dmsotreat
cultur
vero
huvec
data
express
percentag
untreat
control
repres
mean
sd
two
vero
three
huvec
independ
experi
done
duplic
dot
line
indic
lc
valu
effect
drug
ad
later
time
hpi
assess
effect
ntz
treatment
viru
protein
synthesi
mock
infect
rvdz
infect
huvec
treat
ntz
immedi
viru
adsorpt
hpi
rv
structur
protein
examin
wb
analysi
nonstructur
protein
examin
due
lack
specif
antibodi
larg
amount
c
protein
synthes
dmsotreat
rvdz
infect
cell
fig
rvdz
result
shown
dosedepend
reduct
viral
protein
product
observ
ntztreat
infect
cultur
lack
chang
band
pattern
band
mobil
suggest
ntz
substanti
affect
posttransl
modif
rv
structur
protein
determin
effect
ntz
spatial
distribut
rv
protein
infect
cell
huvec
treat
ntz
follow
infect
moi
hpi
rv
structur
protein
visual
infect
cell
immunofluoresc
microscopi
differ
ntztreat
control
cell
diffus
distribut
c
protein
cytoplasm
shown
immunostain
show
minor
chang
tight
perinuclear
transgolgi
local
control
cell
diffus
perinuclear
local
ntztreat
cell
fig
cellular
distribut
chang
coloc
transgolgi
control
cell
diffus
cytoplasm
distribut
mani
ntztreat
cell
ntztreat
cell
form
vesicular
structur
evenli
distribut
cytoplasm
fig
data
suggest
ntz
affect
complex
format
intracellular
traffick
investig
whether
ntz
effect
rv
genom
rna
synthesi
perform
rnafish
analysi
rvdz
infect
huvec
treatment
ntz
use
probe
set
specif
posit
neg
rna
strand
rv
signal
dot
cell
detect
infect
control
cell
lack
substanti
reduc
ntztreat
cell
fig
accord
report
result
perelygina
et
al
negativestrand
rna
molecul
detect
control
cultur
wherea
rvhybrid
signal
ntztreat
cell
less
dotcel
fig
rvdz
result
shown
signal
produc
influenza
probe
set
shown
data
suggest
ntz
inhibit
synthesi
posit
neg
strand
rv
rna
interestingli
amount
gapdh
mrna
posit
assay
control
also
substanti
reduc
ntztreat
cultur
fig
confirm
result
use
differ
refer
gene
fig
quantit
fluoresc
intens
imagej
reveal
fold
reduct
gapdh
rna
signal
fig
result
suggest
either
inhibit
cellular
rna
synthesi
ntz
activ
rna
degrad
pathway
rnasel
test
hypothesi
cell
monolay
treat
either
ntz
dmso
actinomycin
inhibitor
cellular
transcript
nascent
rna
fluoresc
label
use
rnaclick
chemistri
analysi
microscop
imag
show
size
fluoresc
intens
nucleoli
region
ribosom
rna
synthesi
decreas
ntz
treatment
fig
total
nascent
rna
level
per
nucleu
determin
quantit
fluoresc
intens
nuclei
n
condit
imagej
found
reduc
ntztreat
sampl
compar
level
control
sampl
fig
thu
ntz
inhibit
synthesi
viral
cellular
rna
observ
appar
effect
ntz
lack
effect
interferon
therapi
singl
pid
patient
sever
skin
granuloma
posit
rv
antigen
twomonth
peginterferon
treatment
given
prior
ntz
elimin
reduc
amount
rv
antigen
lesion
patient
inabl
interferonalpha
therapi
reduc
rv
excret
also
report
infant
congenit
rubella
syndrom
arvin
et
al
follow
treatment
mg
oral
ntz
two
month
rv
clear
wound
patient
clinic
improv
observ
sever
possibl
reason
first
although
associ
skin
granuloma
rv
infect
clearli
demonstr
individu
primari
immun
defici
bodem
et
al
perelygina
et
al
causal
role
rv
infect
format
granuloma
yet
proven
howev
absenc
rv
rna
unaffect
skin
bodem
et
al
unpublish
observ
detect
rv
granuloma
intern
organ
pid
patient
neven
et
al
unpublish
observ
suggest
causal
cours
lesion
develop
year
even
decad
vaccin
causal
determin
like
requir
prospect
studi
longterm
follow
patient
advancedextens
case
lesion
persist
decad
one
would
expect
take
long
time
reach
complet
clinic
histolog
cure
elimin
foreign
antigen
best
furthermor
chronic
infect
may
caus
longterm
fig
effect
ntz
rv
protein
huvec
wb
analysi
rubella
structur
protein
huvec
infect
rvdz
moi
mockinfect
expos
ntz
vehicl
h
protein
extract
ripa
buffer
separ
nonreduc
nupag
gel
blot
probe
rubella
specif
antibodi
identifi
rv
structur
protein
c
two
c
band
indic
arrow
blot
also
probe
mab
demonstr
equal
protein
load
b
immunofluoresc
analysi
dpi
rubella
structur
protein
huvec
monolay
treat
ntz
follow
infect
moi
pfuwel
insert
repres
enlarg
imag
globular
structur
repres
result
two
independ
experi
shown
b
perhap
perman
damag
skin
addit
secondari
bacteri
skin
infect
ntz
treatment
may
also
interf
heal
process
howev
ntz
treatment
may
effect
stop
develop
newlyform
lesion
prevent
rv
spread
subsequ
format
granuloma
new
locat
confirm
ntz
antirubella
activ
vitro
investig
molecular
mechan
ntz
antirubella
action
use
cell
cultur
model
document
dosedepend
inhibitori
effect
ntz
rv
infect
independ
viral
strain
ic
valu
determin
similar
ntz
ic
valu
virus
influenza
coronaviru
hepat
c
rang
indic
good
antivir
activ
drug
rossignol
also
demonstr
ntz
suppress
multipl
postentri
stage
rv
infect
observ
virus
la
frazia
et
al
shi
et
al
wang
et
al
effect
earli
stage
replic
cycl
complet
block
rv
infect
peak
concentr
drug
c
max
human
plasma
receiv
singl
oral
dose
ntz
broekhuysen
et
al
alinia
packag
insert
present
antivir
mechan
ntz
fulli
elucid
sinc
ntz
inhibit
replic
variou
dna
virus
rna
virus
use
differ
replic
strategi
suggest
cellular
pathway
eg
capmedi
translat
ertogolgi
traffick
intracellular
ca
regulatori
pathway
might
affect
rather
virusspecif
target
ashiru
et
al
elazar
et
al
rossignol
et
al
show
level
cellular
rna
transcript
ntztreat
cell
reduc
level
cellular
mrna
may
drop
severalfold
also
demonstr
synthesi
neg
posit
rna
strand
rv
substanti
inhibit
inhibit
viral
rna
replic
ntz
also
report
japanes
enceph
je
viru
shi
et
al
howev
virus
eg
influenza
hepat
b
viru
inhibit
synthesi
viral
genom
detect
ntz
shown
act
posttransl
level
block
matur
traffick
envelop
glycoprotein
virus
stachulski
et
al
sinc
viral
rna
replic
transcript
depend
multipl
fig
inhibit
nascent
cellular
rna
synthesi
ntz
huvec
monolay
treat
ntz
dmso
h
posit
control
cell
treat
inhibitor
cellular
rna
transcript
actinomycin
actd
h
follow
treatment
cell
metabol
label
mm
uridin
newli
synthes
rna
detect
use
click
chemistri
azidederivat
alexa
fluor
imag
acquir
use
zeiss
fluoresc
microscop
insert
repres
enlarg
imag
nuclei
note
reduc
total
fluoresc
intens
nuclei
follow
ntz
treatment
comparison
vehicl
control
size
reduct
dispers
nucleoli
ribosom
rna
ntz
treat
cell
b
total
fluoresc
nucleu
determin
use
imagej
averag
n
nuclei
condit
standard
deviat
mean
shown
p
cellular
accessori
protein
cellular
rna
polymeras
lai
ntz
interfer
viral
cellular
rna
synthesi
could
molecular
mechan
may
mediat
ntz
antivir
action
rv
like
je
replic
rv
rna
start
product
negativestrand
rna
templat
switch
synthesi
positivestrand
genom
subgenom
rna
hpi
liang
gillam
rv
estim
produc
copi
negativestrand
rna
per
cell
perelygina
et
al
thu
negativestrand
rna
synthesi
may
sensit
inhibitor
rna
replic
positivestrand
rna
synthesi
could
explain
ntz
effect
administ
soon
rv
infect
also
demonstr
ntz
could
block
rv
product
late
stage
infect
hpi
probabl
affect
complex
format
andor
ertogolgi
traffick
must
form
correctli
fold
heterodim
er
order
export
golgi
rv
particl
assembl
hobman
et
al
ntz
shown
deplet
ca
er
result
perturb
fold
matur
secret
transmembran
protein
transfer
within
er
ergolgi
export
ashiru
et
al
demonstr
lack
coloc
larg
proport
suggest
perturb
complex
format
alter
local
structur
protein
would
anticip
neg
effect
virion
assembl
despit
neg
effect
multipl
cellular
pathway
standard
oral
dose
ntz
well
toler
pid
patient
rv
posit
granuloma
twomonth
therapi
ntz
shown
safe
children
adult
sever
placebocontrol
clinic
trial
rate
occurr
advers
event
differ
significantli
ntz
placebo
treat
group
amadi
et
al
haffizulla
et
al
rossignol
current
unclear
whether
identifi
cellular
mechan
respons
reduct
rv
antigen
patient
lesion
exampl
immunomodulatori
effect
ntz
hong
et
al
trabattoni
et
al
may
play
role
follow
oral
administr
ntz
rapidli
adsorb
gastrointestin
tract
hydrolyz
form
tizoxanid
desacetyl
nitazoxanid
metabol
form
tizoxanid
glucuronid
broekhuysen
et
al
tizoxanid
least
activ
vitro
ntz
differ
virus
tizoxanid
glucuronid
exhibit
moder
antivir
activ
korba
et
al
la
frazia
et
al
rossignol
secondgener
thiazolid
favor
pharmacokinet
improv
antivir
activ
current
develop
evalu
keeff
rossignol
futur
test
activ
ntz
metabolit
new
gener
thiazolid
eg
activ
deriv
aid
understand
antirv
mechan
thiazolid
vivo
identif
effect
antirv
compound
conclus
demonstr
ntz
potent
antivir
activ
rv
cell
cultur
singl
patient
dose
use
data
suggest
multipl
vitro
mechan
drug
action
includ
inhibit
cellular
viral
rna
synthesi
aberr
traffick
viral
structur
protein
ntz
could
first
drug
effect
treatment
persist
rubella
infect
result
studi
suggest
studi
warrant
evalu
abil
ntz
control
chronic
rubella
infect
find
conclus
report
author
necessarili
repres
offici
posit
unit
state
center
diseas
control
prevent
work
support
core
fund
center
diseas
control
prevent
oulu
univers
hospit
vtr
fund
finnish
medic
foundat
helsinki
univers
hospit
research
fund
